Tonya N. Zeczycki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tonya N. Zeczycki has a total of 195 co-authors. Here are the top co-authors by number of shared publications:
John C. Wallace
School of Molecular and Biomedical Science, University of Adelaide, Adelaide S.A., 5005, Australia
6 shared publicationsMartin St. Maurice
Department of Biological Sciences, Marquette University, P.O. Box 1881, Milwaukee, WI 53201, U.S.A.
6 shared publicationsSarawut Jitrapakdee
Molecular Metabolism Research Group, Department of Biochemistry, Faculty of Science, Mahidol University, Bangkok 10400, Thailand
6 shared publicationsAbdussalam Adina-Zada
School of Chemistry and Biochemistry, University of Western Australia, Crawley, WA 6009, Australia
5 shared publications- Paul V. Attwood
School of Biomedical, Biomolecular and Chemical Sciences, University of Western Australia, Crawley, WA 6009, Australia
5 shared publications Ann L. Menefee
Department of Biochemistry and Molecular Biology, Brody School of Medicine at East Carolina University, Greenville, NC, USA; The East Carolina Diabetes and Obesity Institute, Brody School of Medicine at East Carolina University, Greenville, NC, USA
4 shared publications
Latest Publications
- Open Access
- 10 August 2026
- Published by MDPI AG in Biophysica
- Vol. 6 (4) , 72
Amber Suppressor tRNA-Based Mutagenesis for Positional Semi-Saturated Mutagenesis with Natural Amino Acid Substitutions: An Approach for Mapping Positional Contributions to Protein Function
There is a growing interest in methods that illuminate the contributions of individual positions to a protein’s function by site-saturating mutagenesis. However, a commonly used approach for assessing variant libraries with deep mutational scanning relies on readouts of biological fitness, which is influenced by many protein properties (ligand binding, catalysis, allosteric effector binding, allosteric coupling between effector and substrate, etc.). Biochemical assays are required to distinguish among these factors. To facilitate the generation and biochemical evaluation of the functions of large numbers of substituted positions, we co-express updated plasmids coding a series of amber suppressor tRNA in a high-throughput workflow; these plasmids are available at Addgene. As an example, our goal is to evaluate whether allosteric mechanisms are conserved among homologs. Because homologs often have <50% identity, and up to 30% of a protein’s positions can contribute to allosteric function, we reason that the set of “allosteric” positions likely differs among homologs. Our high-throughput workflow includes the following steps: Step (1) an amber suppressor tRNA-based mutagenesis protocol; Step (2) a robotic system for protein expression/purification and functional assays; and Step (3) a method for aggregating results from multiple substitutions at each position into a composite score.
- 10 August 2026
- Published by MDPI AG in Biophysica
- Vol. 6 (4) , 72
Open AccessAmber Suppressor tRNA-Based Mutagenesis for Positional Semi-Saturated Mutagenesis with Natural Amino Acid Substitutions: An Approach for Mapping Positional Contributions to Protein Function
There is a growing interest in methods that illuminate the contributions of individual positions to a protein’s function by site-saturating mutagenesis. However, a commonly used approach for assessing variant libraries with deep mutational scanning relies on readouts of biological fitness, which is influenced by many protein properties (ligand binding, catalysis, allosteric effector binding, allosteric coupling between effector and substrate, etc.). Biochemical assays are required to distinguish among these factors. To facilitate the generation and biochemical evaluation of the functions of large numbers of substituted positions, we co-express updated plasmids coding a series of amber suppressor tRNA in a high-throughput workflow; these plasmids are available at Addgene. As an example, our goal is to evaluate whether allosteric mechanisms are conserved among homologs. Because homologs often have <50% identity, and up to 30% of a protein’s positions can contribute to allosteric function, we reason that the set of “allosteric” positions likely differs among homologs. Our high-throughput workflow includes the following steps: Step (1) an amber suppressor tRNA-based mutagenesis protocol; Step (2) a robotic system for protein expression/purification and functional assays; and Step (3) a method for aggregating results from multiple substitutions at each position into a composite score.
- Open Access
- 8 July 2026
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 11 (28) , 41479-41489
Selective Reprogramming of Ribosome Assembly and Translational Control during Bacterial Growth Phase Transitions
- 8 July 2026
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 11 (28) , 41479-41489
Open AccessSelective Reprogramming of Ribosome Assembly and Translational Control during Bacterial Growth Phase Transitions
- Open Access
- 5 May 2026
- Published by Springer Nature in Research Square
TACO1 regulates mitochondrial adaptation in hypertension-induced cardiac remodeling and heart failure
Mitochondrial dysfunction drives hypertensive heart failure and reflects impaired oxidative phosphorylation and altered organelle structure. The mechanisms linking hypertensive signaling to mitochondrial translation and architecture remain unclear. TACO1 is a mitochondrial translational activator required for cytochrome c oxidase subunit I synthesis and may regulate respiratory chain assembly. We tested whether angiotensin II type 1 receptor activation disrupts TACO1-dependent translation and drives inner membrane remodeling. Using mRen also known as (mRen2)27 hypertensive rat hearts, we assessed mitochondrial function, ultrastructure, and metabolism. AT1R activation reduced TACO1-dependent COX I translation and produced a selective deficiency in complex IV activity. This impaired oxidative phosphorylation and increased the production of reactive oxygen species. Mitochondria exhibited reduced volume, increased fragmentation, and disrupted cristae organization with lower integrity scores. Hypertensive hearts also showed reduced expression of OPA1 and MICOS components. Metabolomic profiling separated control and heart failure groups and revealed enrichment of amino acid, nucleotide, and mitochondrial energy pathways. Lipidomic analysis identified coordinated changes across lipid classes consistent with altered membrane composition. Pharmacological AT1R inhibition restored COX I translation, rescued complex IV activity, and improved cristae structure. These findings establish a mechanistic link between hypertensive signaling, mitochondrial translation, cristae organization, and metabolic remodeling in heart failure.
- 5 May 2026
- Published by Springer Nature in Research Square
Open AccessTACO1 regulates mitochondrial adaptation in hypertension-induced cardiac remodeling and heart failure
Mitochondrial dysfunction drives hypertensive heart failure and reflects impaired oxidative phosphorylation and altered organelle structure. The mechanisms linking hypertensive signaling to mitochondrial translation and architecture remain unclear. TACO1 is a mitochondrial translational activator required for cytochrome c oxidase subunit I synthesis and may regulate respiratory chain assembly. We tested whether angiotensin II type 1 receptor activation disrupts TACO1-dependent translation and drives inner membrane remodeling. Using mRen also known as (mRen2)27 hypertensive rat hearts, we assessed mitochondrial function, ultrastructure, and metabolism. AT1R activation reduced TACO1-dependent COX I translation and produced a selective deficiency in complex IV activity. This impaired oxidative phosphorylation and increased the production of reactive oxygen species. Mitochondria exhibited reduced volume, increased fragmentation, and disrupted cristae organization with lower integrity scores. Hypertensive hearts also showed reduced expression of OPA1 and MICOS components. Metabolomic profiling separated control and heart failure groups and revealed enrichment of amino acid, nucleotide, and mitochondrial energy pathways. Lipidomic analysis identified coordinated changes across lipid classes consistent with altered membrane composition. Pharmacological AT1R inhibition restored COX I translation, rescued complex IV activity, and improved cristae structure. These findings establish a mechanistic link between hypertensive signaling, mitochondrial translation, cristae organization, and metabolic remodeling in heart failure.
- 20 March 2026
- Published by American Chemical Society (ACS) in ACS Nano Medicine
- Vol. 1 (5) , 1290-1309
Precision Control of Nanoparticle Delivery with Engineered Biomimetic Protein Coronas
- 20 March 2026
- Published by American Chemical Society (ACS) in ACS Nano Medicine
- Vol. 1 (5) , 1290-1309
Precision Control of Nanoparticle Delivery with Engineered Biomimetic Protein Coronas
- Open Access
Precision control of nanoparticle delivery with engineered biomimetic protein coronas
Nanoparticle delivery to tumors remains inefficient, with current nanomedicines achieving only 0.7% injected dose per gram (ID/g) of tumor tissue due to uncontrolled protein corona formation that redirects nanoparticles away from target sites. We engineered biomimetic protein coronas to control nanoparticle-protein interactions and enhance tumor targeting. Competitive binding studies using NMR spectroscopy revealed that transferrin (Tf) and fibronectin (Fn) outcompete albumin (BSA) and immunoglobulin G (IgG) for 15 nm gold nanoparticle surfaces, establishing a binding hierarchy that enables predictable corona composition. Pre-coating nanoparticles with a four-protein combination (BSA+Tf+Fn+IgG) created coronas that selectively enhanced cancer cell uptake while reducing macrophage recognition in vitro. When administered to tumor-bearing mice, these engineered coronas achieved 13 ppm/g tumor accumulation (equivalent to 4% ID/g) representing 6.5-fold improvement over bare nanoparticles and 2.6-fold improvement over PEGylated formulations. Proteomics analysis of secondary coronas formed in human serum revealed that engineered nanoparticles selectively recruit transport and adhesion proteins while limiting immune recognition signatures. The pre-formed coronas maintained targeting protein retention and reduced complement binding compared to controls. Circular dichroism confirmed minimal protein structural perturbation, preserving receptor-binding functionality for active targeting. The strategy harnesses natural protein adsorption processes to create "smart" biological interfaces that simultaneously evade immune clearance and promote tumor cell recognition through multiple receptor pathways. This approach demonstrates the feasibility of treating the coron as a programmable interface, addressing delivery limitations that have hindered clinical translation of cancer nanomedicines.
Open AccessPrecision control of nanoparticle delivery with engineered biomimetic protein coronas
Nanoparticle delivery to tumors remains inefficient, with current nanomedicines achieving only 0.7% injected dose per gram (ID/g) of tumor tissue due to uncontrolled protein corona formation that redirects nanoparticles away from target sites. We engineered biomimetic protein coronas to control nanoparticle-protein interactions and enhance tumor targeting. Competitive binding studies using NMR spectroscopy revealed that transferrin (Tf) and fibronectin (Fn) outcompete albumin (BSA) and immunoglobulin G (IgG) for 15 nm gold nanoparticle surfaces, establishing a binding hierarchy that enables predictable corona composition. Pre-coating nanoparticles with a four-protein combination (BSA+Tf+Fn+IgG) created coronas that selectively enhanced cancer cell uptake while reducing macrophage recognition in vitro. When administered to tumor-bearing mice, these engineered coronas achieved 13 ppm/g tumor accumulation (equivalent to 4% ID/g) representing 6.5-fold improvement over bare nanoparticles and 2.6-fold improvement over PEGylated formulations. Proteomics analysis of secondary coronas formed in human serum revealed that engineered nanoparticles selectively recruit transport and adhesion proteins while limiting immune recognition signatures. The pre-formed coronas maintained targeting protein retention and reduced complement binding compared to controls. Circular dichroism confirmed minimal protein structural perturbation, preserving receptor-binding functionality for active targeting. The strategy harnesses natural protein adsorption processes to create "smart" biological interfaces that simultaneously evade immune clearance and promote tumor cell recognition through multiple receptor pathways. This approach demonstrates the feasibility of treating the coron as a programmable interface, addressing delivery limitations that have hindered clinical translation of cancer nanomedicines.
- 1 December 2025
- Published by American Physiological Society in American Journal of Physiology-Endocrinology and Metabolism
- Vol. 329 (6) , E912-E922
Maternal exercise alters placental proteome in an exercise mode-specific manner
This article highlights the broad and significant changes that occur in the placental proteome in response to different types of maternal exercise. Our findings further reveal that the overall volume of maternal exercise was associated with alterations in nearly 25% of the identified placental proteins, suggesting that both the type and amount of maternal physical activity may play important roles in shaping placental function and possibly contributing to fetal development.
- 1 December 2025
- Published by American Physiological Society in American Journal of Physiology-Endocrinology and Metabolism
- Vol. 329 (6) , E912-E922
Maternal exercise alters placental proteome in an exercise mode-specific manner
This article highlights the broad and significant changes that occur in the placental proteome in response to different types of maternal exercise. Our findings further reveal that the overall volume of maternal exercise was associated with alterations in nearly 25% of the identified placental proteins, suggesting that both the type and amount of maternal physical activity may play important roles in shaping placental function and possibly contributing to fetal development.
- Open Access
Deletion of Murine Endothelial Bag3 Alters the Cellular Proteome Among Organs of Origin
BAG3 (Bcl-2 associated athanogene 3) is a multifunctional protein with pleiotropic effects in multiple cell types. Despite our knowledge of its role in cardiovascular disease, its specific role in endothelial cells (ECs) is unknown. The purpose of this study was to identify differences in the EC proteome of multiple tissues before and after cell specific deletion of Bag3 . We hypothesized that BAG3 loss would uniquely alter the baseline proteome landscape of ECs in each tissue. Cdh5(PAC)-CreERT2; Bag3 f/f mice received tamoxifen (KO; n=18) or vehicle (WT; n=18) and tissues (brain, heart, lung, and peripheral skeletal muscle-skm) were collected for FACS sorting of ECs from equal numbers of male and female mice at >22 weeks of age, followed by LC-MS/MS label-free proteomics. Initial comparisons of the WT proteomes between tissues revealed differential abundance of EC proteins (p<0.05), including: 379 brain v heart; 325 brain v lung; 501 brain v skm; 354 heart v lung; 107 heart v skm; and 442 lung v skm. Additionally, the EC mitochondrial proteome was unique to each tissue of origin, with significantly (p<0.05) higher proportions dedicated to complexes I, III, IV and V, in heart compared to the other tissues. KO demonstrated the largest effect on skm ECs, increasing 30 proteins (Mybpc2 L2FC=4.81; PFKM L2FC=3.02) and decreasing 65 (CDC42 L2FC=-2.44; Prpf8 L2FC=-2.24). Overall, these results demonstrate that the EC proteome of different tissues is unique and that the loss of BAG3 in these cells differentially alters a small proportion of the EC specific proteome.
Open AccessDeletion of Murine Endothelial Bag3 Alters the Cellular Proteome Among Organs of Origin
BAG3 (Bcl-2 associated athanogene 3) is a multifunctional protein with pleiotropic effects in multiple cell types. Despite our knowledge of its role in cardiovascular disease, its specific role in endothelial cells (ECs) is unknown. The purpose of this study was to identify differences in the EC proteome of multiple tissues before and after cell specific deletion of Bag3 . We hypothesized that BAG3 loss would uniquely alter the baseline proteome landscape of ECs in each tissue. Cdh5(PAC)-CreERT2; Bag3 f/f mice received tamoxifen (KO; n=18) or vehicle (WT; n=18) and tissues (brain, heart, lung, and peripheral skeletal muscle-skm) were collected for FACS sorting of ECs from equal numbers of male and female mice at >22 weeks of age, followed by LC-MS/MS label-free proteomics. Initial comparisons of the WT proteomes between tissues revealed differential abundance of EC proteins (p<0.05), including: 379 brain v heart; 325 brain v lung; 501 brain v skm; 354 heart v lung; 107 heart v skm; and 442 lung v skm. Additionally, the EC mitochondrial proteome was unique to each tissue of origin, with significantly (p<0.05) higher proportions dedicated to complexes I, III, IV and V, in heart compared to the other tissues. KO demonstrated the largest effect on skm ECs, increasing 30 proteins (Mybpc2 L2FC=4.81; PFKM L2FC=3.02) and decreasing 65 (CDC42 L2FC=-2.44; Prpf8 L2FC=-2.24). Overall, these results demonstrate that the EC proteome of different tissues is unique and that the loss of BAG3 in these cells differentially alters a small proportion of the EC specific proteome.
- Open Access
Phase-Specific Antibiotic Resistance Mechanisms in an Escherichia coli B Strain
The majority of antibiotics developed to date target the fast-growing phase of bacteria, which typically occurs during active infection and resembles the exponential growth phase of laboratory-grown cultures. However, many pathogenic bacteria in the human body occupy environments where nutrients are limited and persist in a low-metabolic state, mirroring the stationary phase observed in laboratory-grown cultures. Bacteria in this latter phase are generally more resistant to antibiotics and are often responsible for recurrent infections. A comprehensive understanding of metabolic processes in both the exponential and stationary phases of bacterial growth could facilitate the development of phase-specific antibiotics. In this study, we adopted an untargeted proteomics approach to establish similarities and differences in the exponential and stationary phase proteome landscapes in BLR (DE3) cells, an Escherichia coli B strain. Our findings are consistent with previous studies, which show that metabolic processes such as translation and ribosome biogenesis decrease during the stationary phase compared to the fast-growing exponential phase, whereas tricarboxylic acid cycle activity increases. Importantly, our data reveal that distinct antibiotic resistance pathways are activated during the exponential and stationary phases, underscoring the potential for developing phase-specific antibiotic therapies.
Open AccessPhase-Specific Antibiotic Resistance Mechanisms in an Escherichia coli B Strain
The majority of antibiotics developed to date target the fast-growing phase of bacteria, which typically occurs during active infection and resembles the exponential growth phase of laboratory-grown cultures. However, many pathogenic bacteria in the human body occupy environments where nutrients are limited and persist in a low-metabolic state, mirroring the stationary phase observed in laboratory-grown cultures. Bacteria in this latter phase are generally more resistant to antibiotics and are often responsible for recurrent infections. A comprehensive understanding of metabolic processes in both the exponential and stationary phases of bacterial growth could facilitate the development of phase-specific antibiotics. In this study, we adopted an untargeted proteomics approach to establish similarities and differences in the exponential and stationary phase proteome landscapes in BLR (DE3) cells, an Escherichia coli B strain. Our findings are consistent with previous studies, which show that metabolic processes such as translation and ribosome biogenesis decrease during the stationary phase compared to the fast-growing exponential phase, whereas tricarboxylic acid cycle activity increases. Importantly, our data reveal that distinct antibiotic resistance pathways are activated during the exponential and stationary phases, underscoring the potential for developing phase-specific antibiotic therapies.
- Open Access
- 11 April 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (15) , eadu5511
Acute myeloid leukemia mitochondria hydrolyze ATP to support oxidative metabolism and resist chemotherapy
OxPhos inhibitors have struggled to show a clinical benefit because of their inability to distinguish healthy from cancerous mitochondria. Herein, we describe an actionable bioenergetic mechanism unique to acute myeloid leukemia (AML) mitochondria. Unlike healthy cells that couple respiration to ATP synthesis, AML mitochondria support inner-membrane polarization by consuming ATP. Matrix ATP consumption allows cells to survive bioenergetic stress. Thus, we hypothesized AML cells may resist chemotherapy-induced cell death by reversing the ATP synthase reaction. In support, BCL-2 inhibition with venetoclax abolished OxPhos flux without affecting mitochondrial polarization. In surviving AML cells, sustained mitochondrial polarization depended on matrix ATP consumption. Mitochondrial ATP consumption was further enhanced in AML cells made refractory to venetoclax, consequential to down-regulations in the endogenous F 1 -ATPase inhibitor ATP5IF1. Knockdown of ATP5IF1 conferred venetoclax resistance, while ATP5IF1 overexpression impaired F 1 -ATPase activity and heightened sensitivity to venetoclax. These data identify matrix ATP consumption as a cancer cell–intrinsic bioenergetic vulnerability actionable in the context of BCL-2 targeted chemotherapy.
- 11 April 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (15) , eadu5511
Open AccessAcute myeloid leukemia mitochondria hydrolyze ATP to support oxidative metabolism and resist chemotherapy
OxPhos inhibitors have struggled to show a clinical benefit because of their inability to distinguish healthy from cancerous mitochondria. Herein, we describe an actionable bioenergetic mechanism unique to acute myeloid leukemia (AML) mitochondria. Unlike healthy cells that couple respiration to ATP synthesis, AML mitochondria support inner-membrane polarization by consuming ATP. Matrix ATP consumption allows cells to survive bioenergetic stress. Thus, we hypothesized AML cells may resist chemotherapy-induced cell death by reversing the ATP synthase reaction. In support, BCL-2 inhibition with venetoclax abolished OxPhos flux without affecting mitochondrial polarization. In surviving AML cells, sustained mitochondrial polarization depended on matrix ATP consumption. Mitochondrial ATP consumption was further enhanced in AML cells made refractory to venetoclax, consequential to down-regulations in the endogenous F 1 -ATPase inhibitor ATP5IF1. Knockdown of ATP5IF1 conferred venetoclax resistance, while ATP5IF1 overexpression impaired F 1 -ATPase activity and heightened sensitivity to venetoclax. These data identify matrix ATP consumption as a cancer cell–intrinsic bioenergetic vulnerability actionable in the context of BCL-2 targeted chemotherapy.
- Open Access
- 7 February 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (4) , 1398
Relative Quantitation of EFNA1 Expression in Mouse Heart Tissue Histologic Sections Using MALDI-MSI
EFNA1 (ephrinA1), a highly expressed tyrosine kinase receptor-ligand in healthy cardiomyocytes, is reduced following myocardial infarction (MI). A single intramyocardial injection of chimeric EFNA1-Fc at the time of ischemia mitigates the injury in both reperfused and non-reperfused mouse myocardium by reducing apoptosis, necrosis, and inflammation. Recently, we have successfully imaged and qualitatively identified endogenous EFNA1 pre- and post-MI using matrix-assisted laser desorption ionization mass spectrometry imaging (MALDI-MSI) coupled with a time-of-flight mass spectrometer (MALDI/TOF MS). Building on our previous work, we are currently focused on understanding and characterizing EFNA1’s role in cardiac tissue by developing an integrated quantitative method to determine endogenous levels of EFNA1 using MALDI-MSI technologies. Herein, we have optimized a method for the relative quantitation of endogenous tryptic EFNA1 peptides detected in the murine heart as compared with routine western blotting. In healthy myocardium, there was approximately 50 ng of endogenous EFNA1 per section of 9.43 mm3 tissue, or roughly 12 pg/µg of homogenized tissue. MALDI-MSI thus provides a tool for determining the anatomical distribution and relative quantitation of endogenous EFNA1 in cardiac tissue. Future applications of these tools will allow us to investigate the dynamic changes in EFNA1 expression profile that occur in pathological states such as myocardial infarction and upon therapeutic treatments.
- 7 February 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (4) , 1398
Open AccessRelative Quantitation of EFNA1 Expression in Mouse Heart Tissue Histologic Sections Using MALDI-MSI
EFNA1 (ephrinA1), a highly expressed tyrosine kinase receptor-ligand in healthy cardiomyocytes, is reduced following myocardial infarction (MI). A single intramyocardial injection of chimeric EFNA1-Fc at the time of ischemia mitigates the injury in both reperfused and non-reperfused mouse myocardium by reducing apoptosis, necrosis, and inflammation. Recently, we have successfully imaged and qualitatively identified endogenous EFNA1 pre- and post-MI using matrix-assisted laser desorption ionization mass spectrometry imaging (MALDI-MSI) coupled with a time-of-flight mass spectrometer (MALDI/TOF MS). Building on our previous work, we are currently focused on understanding and characterizing EFNA1’s role in cardiac tissue by developing an integrated quantitative method to determine endogenous levels of EFNA1 using MALDI-MSI technologies. Herein, we have optimized a method for the relative quantitation of endogenous tryptic EFNA1 peptides detected in the murine heart as compared with routine western blotting. In healthy myocardium, there was approximately 50 ng of endogenous EFNA1 per section of 9.43 mm3 tissue, or roughly 12 pg/µg of homogenized tissue. MALDI-MSI thus provides a tool for determining the anatomical distribution and relative quantitation of endogenous EFNA1 in cardiac tissue. Future applications of these tools will allow us to investigate the dynamic changes in EFNA1 expression profile that occur in pathological states such as myocardial infarction and upon therapeutic treatments.